Terms ending in 2039
Every in-force patent on Epicentrx, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,357,608 | METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 12,280,123 | Recombinant Adenoviruses Carrying Transgenes In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 12,036,247 | Multiple Transgene Recombinant Adenovirus In force · High confidence | Epicentrx, Inc. | In force | High confidence | |
| US 11,510,901 | METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION In force · High confidence | Epicentrx, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.